Announced Fri, 26 Jun · 18:56 IST
Board approves new subsidiary Wanbury Skin Health Limited
Strategic Transactions View source PDF
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.8%1-day move
₹275.00
prior close
₹274.35
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+1.0+1.1+2.2+1.8+4.8+3.9+3.7+3.5-1.3+24.0———
Up moveDown movePending
AI summary
Wanbury Limited board approved incorporating a new subsidiary, Wanbury Skin Health Limited, in India. The company will hold 82 percent stake via an initial investment of up to Rs 4.1 lakhs (41,000 equity shares at Rs 10 face value). The subsidiary will operate in the pharmaceutical sector. Board also appointed Ernst and Young LLP as Internal Auditor and ABK and Associates as Cost Auditor for FY 2026-27.
Likely market impact
Very small capital outlay for a new pharma subsidiary; likely minimal stock impact. Auditor appointments are routine compliance matters.